Protara Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TARA research report →
Range $12 – $12
Price Chart
About the company
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains.
- CEO
- Jesse Shefferman
- IPO
- 2014
- Employees
- 46
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on TARA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $219.20M
- P/E
- -2.87
- Fwd P/E
- 23.64
- PEG
- -0.17
- P/S
- 0.00
- P/B
- 1.47
- EV/EBITDA
- -2.94
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -41.72%
- ROIC
- -46.81%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-362,000+0.0%
- Op Income
- $-64,549,000
- Net Income
- $-57,439,000-28.8%
- EPS
- $-1.34+38.2%
- OCF Growth
- -57.4%
- FCF Growth
- -57.4%
- 52W High
- $7.82
- 52W Low
- $3.00
- 50D MA
- $4.02
- 200D MA
- $5.20
- Beta
- 1.49
- RSI (14)
- 43
- Avg Volume
- 630.55K
No earnings-call transcripts are available for TARA yet.
- Free Float
- 87.5%
- Shares Outstanding
- 56.20M
- Float Shares
- 49.16M
of shares held by institutions
118 13F filers
Buy/sell ratio 1.13. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group PLC | 5.21M | ▲ 65.39K |
| Blackrock, Inc. | 3.66M | ▲ 268.53K |
| Millennium Management LLC | 3.10M | ▲ 269.96K |
| Velan Capital Investment Management LP | 2.84M | ▲ 10.00K |
| Vanguard Group Inc | 2.39M | ▲ 487.75K |
| Vanguard Capital Management LLC | 2.30M | ▲ 181.12K |
| Blackstone Inc. | 2.27M | 0 |
| Orbimed Advisors LLC | 2.22M | ▲ 2.22M |
| Sio Capital Management, LLC | 1.92M | ▼ 47.97K |
| Acorn Capital Advisors, LLC | 1.75M | 0 |
| Integral Health Asset Management, LLC | 1.50M | ▼ 250.00K |
| 5am Venture Management, LLC | 1.37M | 0 |
Held by 84 ETFs
Biggest fund positions in TARA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | Shefferman Jesse | other | 215,687 |
| Jun 29, 26 | Shefferman Jesse | sell | 215,687 |
| Jun 30, 26 | Shefferman Jesse | other | 14,000 |
| Jun 30, 26 | Shefferman Jesse | other | 7,000 |
| Jun 30, 26 | Shefferman Jesse | other | 4,000 |
| Jun 30, 26 | Shefferman Jesse | other | 5,000 |
| Jun 29, 26 | Shefferman Jesse | other | 215,687 |
| Jun 15, 26 | Levy Richard S | other | 31,000 |
| Jun 15, 26 | Solomon Michael Edward | other | 31,000 |
| Jun 15, 26 | Smith Cynthia | other | 31,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TARA coverage
Recent articles, reports, and earnings notes.
No research on TARA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TARA report →Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline
seekingalpha.com · Aug 11
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Moderate Buy” from Brokerages
defenseworld.net · Aug 4
What Makes Protara Therapeutics (TARA) a New Buy Stock
zacks.com · Jul 21
ROYAL CARIBBEAN GROUP APPOINTS TARA BUNCH TO BOARD OF DIRECTORS
prnewswire.com · Jul 20
Tradeweb Launches TARA, an AI-Powered Research Assistant for Institutional Credit Trading
businesswire.com · Jun 15
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
globenewswire.com · May 20
Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript
seekingalpha.com · May 19
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
globenewswire.com · May 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.